Table 4 Toxicities
Toxicitya, n (%) | Grade of toxicity | p1 | ||||
|---|---|---|---|---|---|---|
G1 | G2 | ≥ G3 | G0 vs G1–2 vs G3–5 | G1–2 vs other | G3–5 vs other | |
Anemia | ||||||
IRD (n = 75) | 32 (42.7%) | 23 (30.7%) | 9 (12.0%) | 0.065 | 0.093 | 0.021 |
RD (n = 129) | 43 (33.3%) | 36 (27.9%) | 33 (25.6%) | |||
Neutropenia | ||||||
IRD (n = 74) | 22 (29.7%) | 13 (17.6%) | 21 (28.4%) | 0.701 | 0.771 | 0.406 |
RD (n = 130) | 48 (36.9%) | 17 (13.1%) | 30 (23.1%) | |||
Thrombocytopenia | ||||||
IRD (n = 75) | 23 (30.7%) | 9 (12.0%) | 16 (21.3%) | 0.744 | 0.661 | 0.863 |
RD (n = 128) | 46 (35.9%) | 14 (10.9%) | 29 (22.6%) | |||
Thrombosis/ Thrombus/Embolism | ||||||
IRD (n = 64) | 3 (4.7%) | – | 3 (4.7%) | 0.460 | 1.000 | 0.349 |
RD (n = 116) | 6 (5.2%) | 1 (0.9%) | 2 (1.7%) | |||
Fatigue | ||||||
IRD (n = 73) | 18 (24.7%) | 29 (39.7%) | 5 (6.8%) | 0.744 | 0.547 | 0.607 |
RD (n = 127) | 28 (22.0%) | 47 (37.0%) | 12 (9.4%) | |||
Infection | ||||||
IRD (n = 70) | 9 (12.9%) | 26 (37.1%) | 15 (21.4%) | 0.008 | 0.005 | 1.000 |
RD (n = 124) | 11 (8.9%) | 25 (20.2%) | 28 (22.5%) | |||
Neuropathyb | ||||||
IRD (n = 75) | 27 (36.0%) | 12 (16.0%) | 3 (4.0%) | 0.011 | 0.144 | 0.049 |
RD (n = 128) | 42 (32.8%) | 10 (7.8%) | – | |||
Nausea, vomiting | ||||||
IRD (n = 67) | 21 (31.3%) | 11 (16.4%) | – | 0.062 | 0.041 | 0.535 |
RD (n = 119) | 25 (21.2%) | 13 (11.0%) | 2 (1.7%) | |||
Anorexia | ||||||
IRD (n = 67) | 19 (28.4%) | 3 (4.5%) | – | 0.400 | 0.398 | 0.537 |
RD (n = 119) | 17 (14.3%) | 14 (11.8%) | 2 (1.7%) | |||
Diarrhea | ||||||
IRD (n = 69) | 14 (20.3%) | 9 (13.0%) | 1 (1.4%) | 0.026 | 0.052 | 0.369 |
RD (n = 118) | 12 (10.2%) | 11 (9.3%) | – | |||
Constipation | ||||||
IRD (n = 65) | 7 (10.8%) | 1 (1.5%) | – | 1.000 | 1.000 | – |
RD (n = 115) | 8 (7.0%) | 6 (5.2%) | – | |||
Exanthema/rash | ||||||
IRD (n = 4) | – | 3 (75.0%) | 1 (25.0%) | 1.000 | 1.000 | 1.000 |
RD (n = 2) | – | 2 (100.0%) | – | |||
Other (max. grade) | ||||||
IRD (n = 48) | 5 (10.4%) | 34 (70.8%) | 9 (18.8%) | 0.185 | 0.185 | 0.185 |
RD (n = 60) | 9 (15.0%) | 32 (53.3%) | 19 (31.7%) | |||